<DOC>
	<DOCNO>NCT00421915</DOCNO>
	<brief_summary>The primary objective study compare efficacy etanercept ( 25 mg , twice weekly ) placebo base percentage patient achieve Assessment Ankylosing Spondylitis ( ASAS ) response criterion ( ASAS 20 % ) week 12 .</brief_summary>
	<brief_title>Study Evaluating Etanercept Treatment Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Main inclusion criterion Diagnosis AS ( define Modified New York Criteria Ankylosing Spondylitis ) . Active AS ( defined average score visual analog scale [ VAS ] ≥ 30 duration intensity morning stiffness 2 following : VAS patient global assessment ≥ 30 ; average VAS nocturnal total pain ≥ 30 ; BASFI ≥ 30 ( score scale 0 100 ) . 18 70 year age . Main exclusion criterion Complete ankylosis ( fusion ) spine . Previous receipt etanercept , antibody tumour necrosis factor alpha ( TNFα ) , TNFα inhibitor . Use diseasemodifying antirheumatic drug ( DMARDs ) hydroxychloroquine , sulphasalazine , methotrexate within 4 week baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>